-
Expert consensus on the diagnosis and treatment of acute hemorrhagic coagulopathy
Time of Update: 2022-10-19
Acute hemorrhagic coagulopathy refers to a pathophysiological state in which the ability of blood to coagulate is acutely impaired. Bleeding is the most common clinical manifestation, but it can also
-
【Prize Research】Chinese hematologist online medical behavior questionnaire under the epidemic, win limited notebooks, prescription pens and other multiple gifts!
Time of Update: 2022-10-19
All teachers who participate in the survey will have the opportunity to drawScientific Research Report MagazineMace 100 points], [2021 CSCO Lymphoma Diagnosis and Treatment Guide], [Fashion U disk], [Hematologist Prescription Pen (blue)].
-
SOHO 2022: Loncastuximab Tesirine Demonstrates Promising Antitumor Activity in Patients with Relapsed/Refractory DLBCL
Time of Update: 2022-10-19
Patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) usually do not respond well with standard therapy. Loncastuximab tesirine（Loncastuximab tesirine-lpyl； Lonca) is a novel ant
-
Clin Lymphoma Myeloma Leuk: MPN-238 single-cell RNA analysis in patients with myelofibrosis showed pelabresib-induced megakaryocyte progenitor and normalization of CD4+ T cells in peripheral blood
Time of Update: 2022-10-19
Baseline and treatment samples were obtained from a randomized pool of 20 patients, and analysis of CD34+ HSPC showed an increased number of megakaryocytes, neutrophils, and erythroid progenitors in patients with myelofibrosis compared to HD, and a significant decrease in bone marrow and B cell lineage progenitor cells.
-
Lancet Haematol: ibethromide plus dexamethasone for severely pretreated late relapsed or refractory multiple myeloma
Time of Update: 2022-10-19
1016/S2352-3026(22)00290-3 Original source:Lonial S, Popat R, Hulin C, et al.
Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial [published online ahead of print, 2022 Oct 6].
doi:10.
doi:10.
doi:10.
doi:10.
-
SOHO 2022: Ivosidenib combined with azacitidine has a better survival benefit than placebo in IDH1-mutant AML
Time of Update: 2022-10-19
According to the results of the Phase III AGILE study (NCT03173248), ivosidenib (Tibsovo) + azacitidine (Vidaza) showed benefits in event-free survival (EFS), overall survival (OS), and clinical response compared with placebo + azacitidine in newly diagnosed IDH1-mutated acute myeloid leukemia (AML).
-
Int Urol Nephrol: Procollagen C protease enhancer-1 and renal failure in multiple myeloma
Time of Update: 2022-10-19
PCPE-1 levels were not affected by other parameters throughout the study population and MM group.
PCPE-1 levels were not affected by other parameters throughout the study population and MM group.
PCPE-1 levels were not affected by other parameters throughout the study population and MM group.
-
Heavy! The legendary BCMA CAR-T was approved for listing by the Ministry of Health, Labor and Welfare of Japan
Time of Update: 2022-10-14
September 28, 2022 / Medical MedClub News / - On September 27, 2022, local time, Legendary Creatures (NASDAQ: LEGN) officially announced that the Ministry of Health, Labor and Welfare (MHLW) of Japan
-
Professor Zhang Zhizhi: Breaking through the dilemma, Seliniso brings new treatment options for PTCL and NK/T-cell lymphoma patients
Time of Update: 2022-10-14
Peripheral T-cell lymphomas (PTCLs) are a highly heterogeneous group of aggressive non-Hodgkin lymphomas (NHLs) that account for 15% to 22% of NHL[1]. According to the 2016 WHO classification, PTCL co
-
In retrospect, these guidelines remain useful for personalized myeloma treatment
Time of Update: 2022-10-14
The novel coronavirus pneumonia (COVID-19) pandemic has created significant challenges in the clinical management of multiple myeloma (MM) patients. Not only the present but also the future. COVID-19
-
Management of Iron Deficiency Anemia in Adults: A List of Recommended Points from the BSG Guidelines!
Time of Update: 2022-10-14
After negative endoscopy of a qualified capsule, it is recommended that further gastrointestinal tests should be considered only if there is still IDA after IRT (quality of evidence: high; Consensus level: 100%; Declaration intensity: strong).
-
2022CSH Lymphocyte Disease Special Session, 100 Schools of Thought, a Hundred Flowers Blooming! It lays a solid foundation for the precise treatment of lymphoma in the future
Time of Update: 2022-10-14
The 17th National Hematology Academic Conference of the Chinese Medical Association was grandly opened in Shanghai on September 23-25, 2022, with the theme of "respect, inheritance, collaboration and
-
2022CSH Prof. Li Wang: Advances in the treatment of diffuse large B-cell lymphoma
Time of Update: 2022-10-14
The 17th National Hematology Academic Conference of the Chinese Medical Association was grandly opened in Shanghai on September 23-25, 2022, with the theme of "respect, inheritance, collaboration and
-
Luo Cancan, et al., Second Affiliated Hospital of Nanchang University: HDAC inhibitor cedabenamide combined with vinetok synergistically inhibits DLBCL growth by downregulating the expression of MYC, BCL2 and TP53
Time of Update: 2022-10-14
IntroductionChinese summary: Objective:To investigate the effect of epigenetic histone deacetylase (HDAC) inhibitor sidabenamide with BCL2 inhibitor Venetok on the growth of diffuse large B-cell lymphoma (DLBCL) and related mechanisms.
-
2022CSH Professor Ma Jun: Inheriting the Century-old Torch, Innovating and Creating the Future: A Review and Prospect of the Development of Hematology in China
Time of Update: 2022-10-14
On September 23-25, 2022, the 17th National Hematology Academic Conference of the Chinese Medical Association was grandly opened at the National Exhibition and Convention Center in Shanghai. The confe
-
CSH Innovation Forum| Han Yue, Xu Yajing, Wang Yu, Zhao Mingfeng, Yi Hongmei invite you to join the academic feast on September 23-25 - the 17th National Hematology Academic Conference of the Chinese Medical Association
Time of Update: 2022-10-14
Listening to the sound of blood and perceiving the rhythm of life, the much-anticipated "17th National Hematology Academic Conference of the Chinese Medical Association" will be grandly opened on Sep
-
At this time, the lymphoma - CSCO Autologous Transplant Working Group 2022 Tour - Lymphoma Special Session (Beijing Station) was grandly held
Time of Update: 2022-10-14
Professor Zhu Jun made a report In the discussion session, Professor Wang Xiaopei of Peking University Cancer Hospital mentioned that ASCT can improve the survival of lymphoma patients, and in the future transplantation work, we need to strengthen the communication between peers in strengthening the grasp of indications, the selection of pretreatment protocols, the control of the number of CD34+ stem cells after mobilization and collection, post-transplant supportive treatment, etc.
-
2022CSH Professor Zhang Xi: Over the lofty mountains, willow dark flowers, a number of guidelines were released, in-depth analysis of GVHD precision prevention and control strategies
Time of Update: 2022-10-14
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective method for the treatment of a variety of blood system diseases, and the success of haplo-type hematopoietic stem cell tra
-
The incidence of leukemia ranks first, and the latest disclosure of cancer data in children in China ...
Time of Update: 2022-10-14
Based on the above results, researchers recommend that cancer incidence and access to health care in children and adolescents include:In the post-pandemic period, relevant departments need to increase the allocation of resources to improve the number of medical facilities and pediatric oncology professionals in underdeveloped areas.
-
【Conference Summary】2022 International Conference on Thrombosis and Hemostasis (ISTH) Cutting-edge Information Sharing
Time of Update: 2022-10-14
The second session is to keep the clouds open to see the moon - progress in the field of pediatrics of hemophilia Professor Wu Runhui of Beijing Children's Hospital affiliated to Capital Medical University shared a number of academic achievements around "Exploration of Treatment Strategies for Children with Hemophilia in China", including 9 abstracts, 1 oral communication and RPTH Editing Award.
